Dr Reddy’s Laboratories dipped 4.5% to Rs 2,299 on the BSE in intra-day trade after media reports suggested that the US Food and Drug Administration (USFDA) issues raised in Establishment Inspection Report (EIR) for the company's injectables unit in Duvvada, Andhra Pradesh.
The BSE said the exchange has sought clarification from Dr Reddy’s Laboratories on January 03, 2018 with reference to news flashed on www.moneycontrol.com dated January 03, 2018 quoting "Dr Reddy's cracks on buzz of issues raised in EIR for Duvvada plant".
The reply is awaited.
Dr Reddy's Laboratories on November 21, 2017, informed the stock
The BSE said the exchange has sought clarification from Dr Reddy’s Laboratories on January 03, 2018 with reference to news flashed on www.moneycontrol.com dated January 03, 2018 quoting "Dr Reddy's cracks on buzz of issues raised in EIR for Duvvada plant".
The reply is awaited.
Dr Reddy's Laboratories on November 21, 2017, informed the stock